Argenx SE extends 2026 gains as Nasdaq listing highlights biotech momentum

By Thomas Clarke, Operations & Strategy desk. Reviewed on June 30, 2026 at 2:42 p.m. ET.

Argenx SE (ISIN NL0010832176) enters the second half of 2026 with a solid share-price performance and a growing footprint in both US and European markets. The biotech group is listed on Nasdaq under the ticker ARGX, giving US investors direct access to the stock through a major exchange.

Nasdaq listing and recent price action

Argenx trades on Nasdaq, where recent market data show the stock at $912.46 at the close on June 29, 2026, with a gain of 2.85 percent for that session according to MarketBeat's ARGX quote page covering the latest price and trading details. The same data set indicates that Argenx shares started 2026 at $840.95, implying an 8.5 percent increase year-to-date as of the current price level.

The MarketBeat overview also highlights a consensus price target of $1,023.39 for Argenx, representing about 12.2 percent potential upside from the recent $912.46 trading price based on aggregated analyst estimates on that platform summarizing Wall Street expectations. While individual ratings vary, the consensus on MarketBeat classifies Argenx as a Moderate Buy, with no sell ratings reported in the current breakdown.

European listing and index exposure

Alongside its US presence, Argenx maintains a primary listing in Europe, where it is a constituent of major benchmarks. Market data from the Financial Times show Argenx SE among the strongest one-day gainers in the BEL 20 index, with the stock quoted at 802.60 EUR, up 2.19 percent, and trading volume of around 12,960 shares over that period in the Belgium market overview. This dual exposure reinforces Argenx's visibility among both European and US investors.

Additional data from Onvista, a German finance portal, place Argenx's share price in the high-700 EUR range, with a reported market capitalization of about 48.48 billion EUR and a free float of 77.07 percent based on its latest snapshot for the NL0010832176 security covering the Argenx SE share. The combination of sizeable market capitalization and high free float is relevant for liquidity and index inclusion.

Role in Belgium equity exposure

Argenx also plays a notable role in exchange-traded fund exposure to Belgian equities. Data from Robinhood on the iShares MSCI Belgium Capped ETF list Argenx SE as one of the largest positions in the fund, accounting for 15.03 percent of assets, second only to Anheuser-Busch InBev, which has a 22.35 percent weight in the EWK holdings overview. For US investors, this ETF weight provides an additional route to participate in Argenx's performance via a diversified vehicle.

The presence of Argenx among the top holdings of a US-listed Belgium ETF reinforces the company's cross-border significance and underlines how its share-price evolution can influence broader country and sector indices. It also illustrates the growing size and relevance of Argenx within the Belgian market, where it features among leading constituents of local benchmarks.

Representative product and business model

Argenx's business model centers on the development of antibody-based therapies in autoimmune disease and related indications, supported by global partnerships and a growing commercial footprint. The company focuses on translating novel immunology insights into clinical-stage and commercial assets, leveraging its expertise in antibody engineering and translational medicine.

Argenx stock and recent trading levels

As of June 29, 2026, at 4:00 p.m. ET, Argenx's American depositary shares on Nasdaq closed at $912.46, with after-hours indications around $912.42 according to MarketBeat's trading summary for ARGX detailing the regular and extended session. European trading in Brussels and on German platforms showed prices in the high-700 to low-800 EUR range around the same period, aligning with Argenx's status as a large-cap biotech name in regional indices.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.